Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) patients and a Dual Stage Ultrafilter (DSU) for water purification. Key products include the OLpur MDHDF filter series (sold in Europe), the OLpur H2H module (pending FDA approval), and the DSU water filter. The company relies on contract manufacturers and has no debt outstanding as of year-end.
Key Financial Metrics
| Metric (in thousands) | 2008 | 2007 |
|---|---|---|
| Product Revenue | $1,473 | $1,196 |
| Gross Margin | $409 | $320 |
| Gross Margin % | 27.8% | 26.8% |
| Net Loss | $(6,337) | $(26,356) |
| Operating Cash Flow | $(5,725) | $(6,442) |
| Cash and Equivalents (Year End) | $2,306 | $3,449 |
| Total Assets | $4,036 | $10,085 |
| Stockholders' Equity | $2,534 | $8,756 |
| Accumulated Deficit | $(87,949) | $(81,612) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 23.2% to $1.473 million, driven primarily by $196,000 in revenue from a U.S. Department of Defense (Office of Naval Research) project and $49,000 from new DSU water filter sales. European dialyzer sales grew only 3% due to a negative price variance from discounted reworked units.
- Net Loss Reduction: Net loss decreased significantly from $26.4 million in 2007 to $6.3 million in 2008. The 2007 loss was inflated by non-cash charges related to the conversion of convertible notes (beneficial conversion features and debt discount amortization totaling ~$18 million), which did not recur in 2008.
- Investment Portfolio: The company sold its Auction Rate Securities (ARS) in July 2008 for $4.1 million, realizing a gain of $114,000 after a prior impairment. Short-term investments dropped from $4.7 million in 2007 to $7,000 in 2008.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 14.9% to $4.7 million, largely due to reduced professional fees and the absence of underwriting fees incurred in 2007.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management and independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. The company has incurred recurring losses since inception and has not generated positive cash flow from operations. Future operations depend on raising additional capital, which may not be available on acceptable terms.
Regulatory Status
- FDA: 510(k) applications for the OLpur H2H module, MD220 filter, and DSU water filter were submitted in late 2008. The FDA requested additional information; the company responded in early 2009. Approval was anticipated in 2009 but remains pending.
- CE Mark: The OLpur MDHDF filter series and DSU hold CE marks for the European market.
Delisting and Trading Status
Subsequent to year-end, the NYSE Alternext US (formerly AMEX) rejected the company's compliance plan and suspended trading on January 22, 2009. As of February 4, 2009, the stock trades on the OTC Bulletin Board under the symbol "NEPH.OB".
Customer Concentration
One customer accounted for 78% of total product sales and 66% of accounts receivable in 2008. The loss of this customer would have a material adverse effect on the business.
Investor Verification Checklist
- Liquidity Runway: Verify current cash burn rate against the $2.3 million cash balance to determine the immediate need for equity financing.
- FDA Approval Timeline: Confirm the status of the FDA's review of the additional information submitted in March 2009 for the H2H and DSU products.
- Customer Dependency: Assess the stability of the single customer representing 78% of revenue and the risk of concentration.
- Stock Liquidity: Evaluate the impact of the delisting from AMEX and the move to the OTC Bulletin Board on the ability to raise capital.
- Government Contract: Verify the status of the $2 million Department of Defense appropriation and the execution of the contract with the Office of Naval Research.